GELESIS HOLDINGS INC (GLS)
US36850R2040 - Common Stock
Taking everything into account, GLS scores 1 out of 10 in our fundamental rating. GLS was compared to 588 industry peers in the Biotechnology industry. GLS has a bad profitability rating. Also its financial health evaluation is rather negative. GLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
GLS had negative earnings in the past year.
In the past year GLS has reported a negative cash flow from operations.
1.2 Ratios
The profitability ratios for GLS are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
GLS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for GLS is higher compared to a year ago.
2.2 Solvency
GLS has an Altman-Z score of -8.60. This is a bad value and indicates that GLS is not financially healthy and even has some risk of bankruptcy.
GLS's Altman-Z score of -8.60 is on the low side compared to the rest of the industry. GLS is outperformed by 77.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.6 |
ROIC/WACCN/A
WACC5.71%
2.3 Liquidity
A Current Ratio of 0.30 indicates that GLS may have some problems paying its short term obligations.
GLS has a Current ratio of 0.30. This is amonst the worse of the industry: GLS underperforms 94.45% of its industry peers.
GLS has a Quick Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
GLS has a worse Quick ratio (0.21) than 94.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
GLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.00%, which is quite impressive.
Looking at the last year, GLS shows a very strong growth in Revenue. The Revenue has grown by 80.37%.
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.08%
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-76.5%
3.2 Future
GLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.67% yearly.
Based on estimates for the next years, GLS will show a very strong growth in Revenue. The Revenue will grow by 68.56% on average per year.
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GLS. In the last year negative earnings were reported.
Also next year GLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GLS's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for GLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GELESIS HOLDINGS INC
NYSE:GLS (4/10/2023, 7:04:01 PM)
After market: 0.1555 0 (-1.95%)0.1586
+0 (+0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.63M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y78.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y